RareiTi Inc., a data-driven early access and clinical patient services company, and Vitaccess Ltd, a multi-award-winning digital real-world evidence (RWE) research and strategy specialist, announce a collaboration offering unique services in RWE to support biopharmaceutical companies in rare disease.

Vitaccess has developed Vitaccess Real™, a cloud-based RWE platform. It comprises device-agnostic data capture and real-time analytics dashboards to quantify patient experience and better understand quality of life, burden of disease, and treatment impact.

RareiTiCARE™, created by RareiTi, is a digital clinical care and monitoring platform, capturing patient insights and RWE at the point of care in pre- and post-approval settings, and aligning healthcare practitioners, patients, and drug developers.

Founded by industry veterans with significant subject matter expertise, both Vitaccess and RareiTi provide innovative solutions to the biopharma industry. These solutions accelerate access to outcomes measures that serve regulators, payers, and health systems all over the world and, importantly, provide unique support for patients.

RareiTi Co-Founder Natalie Douglas says, “Collaborating with Vitaccess makes sense for us when working with biopharma clients seeking to secure approval and reimbursement for rare disease therapies. We can better serve clients by taking a more strategic approach to outcomes research with Vitaccess, adding depth and value with international digital RWE studies and health economics and outcomes research to our patient-centered access programs.”

Dr Mark Larkin, Vitaccess CEO and Founder, comments, “The vast experience that Natalie and her team have in rare disease and early access programs make RareiTi the perfect partner for Vitaccess, with our growing portfolio of rare disease clients. We are excited to capitalize on the natural synergies between market access objectives and access strategies, especially in the complex and high-cost areas of chronic conditions and their management.”

Launching rare disease therapies requires innovation – the solutions offered by this collaboration deliver a significant breakthrough in the optimization of RWE collection pre- and post-approval.

Skip to content